Table 4.

Persistence of gene-modified T cells in blood of patients

CyclePatient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Day/h%Day/h%Day/h%Day/h%Day/h%Day/h%Day/h%
1(1 h)0.16(1 h)0.61(1 h)0.16(1 h)3.9(1 h)2.57(1 h)2.87
(12 h)0(6 h)0(6 h)0.06(6 h)0.241010.05
201010(12 h)030.0250.12
ND50.1330.2231.472042.39270.09
14060.550.4730.352.97
21013013052.74
2(1 h)0.98(1 h)0(1 h)0.52(1 h)1
20(6 h)0.4610(6 h)0.08
ND50.11054.24ND10ND
140130.26130.5730
210.1850
130
300
3(1 h)020.14(1 h)0.48(1 h)0.89
(12 h)0.0430.54130.06(6 h)0.23
10.27210.0710.08NDNDND
20.83<0.03
50.3150.05
140.05130
210
Patient 8
Patient 9
Patient 10
Patient 11
Patient 12
Patient 13
Patient 14
Day/h
%Day/h
%
Day/h
%
Day/h
%
Day/h
%
Day/h
%
Day/h
%
1(1 h)>113.7211.8616.1711.5212.9212.75
(6 h)>123.6622.3360.6120.7822.922.54
1>140.42120.2381.8280.0480.0280.09
2>170.6260131.44140.0190.06150.06
40.43120.44340271.44210.01290.01210.09
130.04180.16550391.36260.06390280.07
250480.013650.03320.04
340.04480.02
760
2(1 h)>112.8812.03
(6 h)0.420.5270.06
1>130.04270NDNDNDND
30.8280
120420
380
  • NOTE: The quantity of neomycin phosphotransferase gene-positive T cells as a percentage of total PBMCs was determined by PCR-ELISA. Although persistence varied between patients, transferred T cells were generally present in large numbers up to day 5 following transfer but were absent or barely detectable by 2 to 3 weeks after transfer.

    Abbreviation: ND, not done.